SCHEMBL6180533

SCHEMBL6180533

COCCN1C(=O)CC(=O)N(Br)C1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.42
ALDH1A1 P00352 5/20 0.42
KMT2A Q03164 3/20 0.36
HTT P42858 2/20 0.36
MEN1 O00255 2/20 0.36
USP2 O75604 2/20 0.36
GAA P10253 2/20 0.36
HSD17B10 Q99714 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 4/20 0.35
LMNA P02545 2/20 0.35
PLA2G7 Q13093 1/20 0.34
HPGD P15428 1/20 0.34
KDM4E B2RXH2 1/20 0.33
POLB P06746 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
BMPR1B O00238 1/20 0.32
BMPR1A P36894 1/20 0.32
TGFBR1 P36897 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4923748 0.88 MAPT (0.44) MAPTALDH1A1KMT2AHTTMEN1
SCHEMBL11807557 0.83 ALDH1A1 (0.40) MAPTALDH1A1KMT2AHTTMEN1
SCHEMBL11803961 0.81 F2 (0.43) MAPTALDH1A1KMT2AHTTMEN1
SCHEMBL8976843 0.77 ALDH1A1 (0.41) MAPTALDH1A1KMT2AHTTMEN1
SCHEMBL11806010 0.77 ALDH1A1 (0.55) MAPTALDH1A1KMT2AHTTMEN1
SCHEMBL32675956 0.74 MAPT (0.53) MAPTALDH1A1KMT2AHTTMEN1
SCHEMBL11694282 0.73 ALDH1A1 (0.51) MAPTALDH1A1KMT2AHTTMEN1
SCHEMBL17717950 0.72 KMT2A (0.55) MAPTALDH1A1KMT2AHTTMEN1
SCHEMBL3629805 0.71 HTT (0.50) MAPTALDH1A1KMT2AHTTMEN1
SCHEMBL7737597 0.70 MAPT (0.50) MAPTALDH1A1KMT2AHTTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919332-B2 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. (US) 2005-07-19 US disclosed
EP-1507535-A1 PYRIMIDINE-2,4,6-TRIONE METALLO-PROTEINASE INHIBITORS Pfizer Products Inc. (US) 2005-02-23 EP disclosed
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors PFIZER INC. 2003-12-18 US disclosed
WO-2003090751-A1 PYRIMIDINE-2, 4, 6-TRIONE METALLO-PROTEINASE INHIBITORS PFIZER PRODUCTS INC. (US) 2003-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232849-A1 N-substituted-heteroaryloxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors MMP8, MMP9, MMP1 MAPT 4691/4885ALDH1A1 390/4885KMT2A 2684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.